On December 9, 2025, Kymera Therapeutics, Inc. announced an agreement to sell 7,000,000 shares of common stock at $86.00 per share, projected to raise approximately $656.1 million for advancing its clinical programs and general corporate purposes. The offering is set to close on December 11, 2025.